NCT06308588招募中1 期
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
详细描述
Primary Objectives
- Phase I: To determine the minimum safe and biologically effective dose of asciminib in combination with blinatumomab
- Phase II: To evaluate the rate of NGS measurable residual disease (MRD) negativity using the clonoSEQ® assay in cohort 1 (newly diagnosed Ph-positive ALL) and the overall response (CR+CRi) rate in cohort 2 (relapsed/refractory disease).
Secondary Objectives
- To evaluate other clinical efficacy endpoints (complete molecular response [CMR] rate, CR rate, relapse-free survival and overall survival)
- To determine the safety of the combination regimen
Exploratory Objectives
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of one of the following:
- •a) Participants ≥18 years of age with previously untreated or minimally pretreated Ph-positive ALL who are not suitable candidates for intensive chemotherapy. Participants who have received no more than one or two courses of chemotherapy with or without other TKIs are considered minimally pretreated and still eligible if they have persistently detectable MRD.
- •i. If they are in morphologic remission at enrollment, they are evaluable only MRD responses, RFS and OS b) Participants ≥ 12 years of age with relapsed/refractory Ph-positive ALL or with previously treated lymphoid blast phase CML
- •Performance status ≤2 (ECOG Scale) if age ≥18 years or Lansky ≥50 if age <18 years
- •Weight ≥40kg
- •Adequate liver function as defined by the following criteria (unless the increased values are judged to be leukemia disease related):
- •Total serum bilirubin ≤ 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome
- •Alanine aminotransferase (ALT) ≤ 3 x ULN, OR
- •Aspartate aminotransferase (AST) ≤ 3 x ULN
- •Adequate renal function defined as:
- •a) Creatinine clearance ≥30 mL/min
- •Adequate pancreatic function as defined by the following criteria:
- •a) Serum lipase and amylase < 1.5 x ULN
- •Adequate cardiac function as assessed clinically by history and physical examination.
- •For females of childbearing potential, a negative urine pregnancy test must be documented
- •Willingness to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after completion of study participation. For women of child-bearing potential, adequate methods of contraception include: complete abstinence, hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), intrauterine device (IUD), tubal Ligation or hysterectomy, subject/partner post vasectomy, implantable or injectable contraceptives, and condoms plus spermicide
- •Ability to understand and the willingness to sign a written informed consent document.
- •Signed informed consent
排除标准
- •Active serious infection not controlled by oral or intravenous antibiotics.
- •Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year.
- •Active Grade III-V cardiac failure as defined by the New York Heart Association Criteria.
- •Prolonged QTc interval on pre-entry electrocardiogram (> 470 msec) unless corrected after electrolyte replacement or approved by cardiologist
- •History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis. (Participants with active CNS leukemia will NOT be excluded)
- •Treatment with any investigational antileukemic agents or chemotherapy agents in the last 7 days before study entry, unless full recovery from side effects has occurred or patient has rapidly progressive disease judged to be life-threatening by the investigator. Cytarabine 2 g/m2 (or alternative) for cytoreduction is permitted.
- •Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and be willing to practice methods of contraception. Women do not have childbearing potential if they have had a hysterectomy or are postmenopausal without menses for 12 months. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.
研究组 & 干预措施
Blinatumomab + Asciminib
Experimental
Participants found to be eligible to take part in this study will receive 5 cycles of blinatumomab and asciminib, followed by asciminib alone for as long as it benefits the participant.
Participants will receive blinatumomab as a continuous (non-stop) infusion on Days 4-31 of Cycle 1 and on Days 1-28 of Cycles 2-5.
Participants will take asciminib by mouth 2 times every day during this study.
干预措施: Asciminib (Drug)
Blinatumomab + Asciminib
Experimental
Participants found to be eligible to take part in this study will receive 5 cycles of blinatumomab and asciminib, followed by asciminib alone for as long as it benefits the participant.
Participants will receive blinatumomab as a continuous (non-stop) infusion on Days 4-31 of Cycle 1 and on Days 1-28 of Cycles 2-5.
Participants will take asciminib by mouth 2 times every day during this study.
干预措施: Blinatumomab (Drug)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsB-Cell Acute Lymphoblastic Leukemia, AdultNCT03160079University of California, San Diego16
撤回
1 期
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaLeukemia, B-cellLymphoma, B-CellNCT03605589Children's Hospital Medical Center, Cincinnati
进行中（未招募）
2 期
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaPhiladelphia Chromosome-PositiveAcute Lymphoblastic LeukemiaNCT04329325Memorial Sloan Kettering Cancer Center17
招募中
2 期
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)Down SyndromeRecurrent B Acute Lymphoblastic LeukemiaNCT04546399National Cancer Institute (NCI)461
招募中
2 期
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBCR-ABL1 Fusion Protein ExpressionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemiat(9;22)Acute Lymphoblastic LeukemiaNCT03263572M.D. Anderson Cancer Center90